logo-loader
viewScancell Holdings PLC

Scancell Holdings close to securing further patent protection over the IP underpinning its Moditope platform

"The utility of the Moditope technology is increasingly being recognised as a novel and important immuno-therapeutic approach in the treatment of cancer, as evidenced by the expansion of our patent portfolio and selection for presentation on the international stage," chief executive Cliff Holloway said

Scancell Holdings PLC -

Scancell Holdings PLC (LON:SCLP) said it is close securing to further protection for its technology from the European Patent Office.

The patent will cover the firm’s modified enolase peptides and adds a further layer of legal security over its pipeline of Moditope vaccines for the treatment of cancer.

"The utility of the Moditope technology is increasingly being recognised as a novel and important immuno-therapeutic approach in the treatment of cancer, as evidenced by the expansion of our patent portfolio and selection for presentation on the international stage," chief executive Cliff Holloway said.

In the same announcement investors were told chief scientific officer, Professor Lindy Durrant, has been invited to make a presentation on the discovery of the Moditope and its potential use in patients with solid tumours.

She will be attending the NeoAg Summit in Boston on Friday 22 November.

Quick facts: Scancell Holdings PLC

Price: 5.45 GBX

LSE:SCLP
Market: LSE
Market Cap: £25.36 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Scancell Holdings PLC named herein, including the promotion by the Company of Scancell Holdings PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

2 min read